76 related articles for article (PubMed ID: 20402250)
1. [Ki-67 and cyclin A--prognostic factors in breast cancer. Time to introduce proliferation markers in clinical routine].
Ahlin C; Fernö M; Amini RM; Tolockiene E; Blomqvist C; Bergh J; Fjällskog ML
Lakartidningen; 2010 Mar 10-16; 107(10):672-5. PubMed ID: 20402250
[No Abstract] [Full Text] [Related]
2. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.
Penault-Llorca F; Abrial C; Raoelfils I; Chollet P; Cayre A; Mouret-Reynier MA; Thivat E; Mishellany F; Gimbergues P; Durando X
Oncologist; 2008 Dec; 13(12):1235-45. PubMed ID: 19091781
[TBL] [Abstract][Full Text] [Related]
3. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?
Ahlin C; Aaltonen K; Amini RM; Nevanlinna H; Fjällskog ML; Blomqvist C
Histopathology; 2007 Oct; 51(4):491-8. PubMed ID: 17711446
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients.
Wiesner FG; Magener A; Fasching PA; Wesse J; Bani MR; Rauh C; Jud S; Schrauder M; Loehberg CR; Beckmann MW; Hartmann A; Lux MP
Breast; 2009 Apr; 18(2):135-41. PubMed ID: 19342238
[TBL] [Abstract][Full Text] [Related]
5. Proliferation marker Ki-67 in early breast cancer.
Urruticoechea A; Smith IE; Dowsett M
J Clin Oncol; 2005 Oct; 23(28):7212-20. PubMed ID: 16192605
[TBL] [Abstract][Full Text] [Related]
6. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
7. Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Hrushesky WJ; Retsky M; Baum M; Demicheli R
J Natl Cancer Inst; 2007 Jul; 99(13):1053; author reply 1053-4. PubMed ID: 17596578
[No Abstract] [Full Text] [Related]
8. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
[TBL] [Abstract][Full Text] [Related]
10. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
Koda M; Sulkowska M; Kanczuga-Koda L; Tomaszewski J; Kucharczuk W; Lesniewicz T; Cymek S; Sulkowski S
Oncol Rep; 2007 Jul; 18(1):113-9. PubMed ID: 17549355
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F
Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients.
Mehdipour P; Pirouzpanah S; Sarafnejad A; Atri M; Shahrestani ST; Haidari M
Cell Biol Int; 2009 Oct; 33(10):1050-6. PubMed ID: 19555767
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.
Aas T; Geisler S; Helle H; Børresen-Dale AL; Lønning PE; Akslen LA
Oncol Rep; 2005 Mar; 13(3):525-30. PubMed ID: 15706428
[TBL] [Abstract][Full Text] [Related]
16. A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer.
Mu K; Li L; Yang Q; Yun H; Kharaziha P; Ye DW; Auer G; Lagercrantz SB; Zetterberg A
Ann Diagn Pathol; 2015 Aug; 19(4):243-8. PubMed ID: 26049669
[TBL] [Abstract][Full Text] [Related]
17. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers.
Baak JP; Gudlaugsson E; Skaland I; Guo LH; Klos J; Lende TH; Søiland H; Janssen EA; Zur Hausen A
Breast Cancer Res Treat; 2009 May; 115(2):241-54. PubMed ID: 18665447
[TBL] [Abstract][Full Text] [Related]
18. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
[TBL] [Abstract][Full Text] [Related]
19. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
20. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
